What is the percentage risk of malignancy in a benign mixed tumor (pleomorphic adenoma) transforming into a malignant mixed tumor (carcinosarcoma)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk of Malignant Transformation in Pleomorphic Adenoma

The risk of malignant transformation from benign pleomorphic adenoma (mixed tumor) to carcinoma ex pleomorphic adenoma ranges from 5-25% in untreated patients, typically occurring after 15-20 years, with most studies reporting rates between 10-14%. 1, 2

Documented Transformation Rates

  • Malignant transformation occurs in 5-25% of untreated pleomorphic adenomas, with the risk increasing substantially with duration of the tumor 1
  • In a clinicopathologic review of major salivary gland tumors, carcinoma ex pleomorphic adenoma accounted for approximately 10% of all salivary gland carcinomas in both parotid and submandibular glands 3
  • A study examining 65 benign mixed tumors with atypical features found that 13.8% (9 of 65 cases) underwent malignant transformation during follow-up 2

Timeline and Warning Signs

  • The typical duration from benign pleomorphic adenoma onset to malignant transformation averages 15-20 years, with one study documenting a range of 2-40 years (mean 17.8 years) 1
  • Warning symptoms of malignant transformation are present in most cases and include rapid tumor enlargement, pain, and facial nerve palsy 1
  • These clinical changes should prompt immediate re-evaluation, as they indicate potential malignant conversion 1

Risk Factors for Transformation

Histologic Features

  • Prominent zones of hyalinization in the benign tumor significantly correlate with increased risk of malignant transformation (P < 0.05) 2
  • Moderate to high mitotic activity in the benign tumor suggests elevated transformation risk 2
  • Other atypical features (hypercellularity, capsule violation, necrosis, cellular anaplasia) showed trends toward increased risk but did not reach statistical significance 2

Clinical Factors

  • Submandibular gland location carries higher risk compared to parotid gland 2
  • Older patient age at initial diagnosis correlates with increased transformation likelihood 2
  • Large tumor size is associated with greater malignant potential 2
  • Untreated or inadequately treated tumors have substantially higher transformation rates 1

Types of Malignant Transformation

The term "malignant mixed tumor" encompasses three distinct entities, with vastly different frequencies 3, 4:

  • Carcinoma ex pleomorphic adenoma: The most common type, accounting for the vast majority of malignant transformations 1, 3
  • Carcinosarcoma (true malignant mixed tumor): Extremely rare, with malignancy in both epithelial and mesenchymal components 4
  • Metastasizing pleomorphic adenoma: The rarest subtype, where histologically benign-appearing tissue metastasizes 5

Clinical Implications

  • The best prevention strategy is early and radical removal of all major salivary gland tumors, as this eliminates the substrate for malignant transformation 1
  • Fine needle aspiration biopsy has insufficient sensitivity (60%) and accuracy (46%) for detecting malignant transformation in pleomorphic adenoma 1
  • Five-year survival rates for carcinoma ex pleomorphic adenoma range from 30-76%, with better outcomes (87.5% in one series) when treated with surgery alone or combined with postoperative radiation 1, 3

Common Pitfalls

  • Do not rely solely on fine needle aspiration to exclude malignancy in long-standing pleomorphic adenomas, as the false-negative rate is substantial 1
  • Do not adopt a "watch and wait" approach for pleomorphic adenomas, as transformation risk increases dramatically with time, particularly after 15-20 years 1
  • Do not dismiss new symptoms (pain, rapid growth, nerve involvement) in patients with known pleomorphic adenoma, as these strongly suggest malignant transformation 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.